Accelerating genetic progress

During the year, progress against our strategic objectives included:

1

Increasing Genetic Control and Product Differentiation 

  • Continuing to develop our range of industry-leading genetics and beginning to assimilate genes acquired from Hermitage Genetics
  • Collaborating with R&D colleagues and external partners on long-term development programmes, including our investigational gene-editing project to produce animals resistant to PRRSv
2

Targeting Key Markets and Segments 

  • Increasing our share of business with large producers around the world, so we now work with over 70% of the largest global accounts
  • Maintaining our progress in Europe (achieving growth of 26% and continuing to see the benefits of our tailored strategy for China (with growth of 82%)
  • Strengthening our supply chain to support markets around the world by upgrading several sites and incorporating Hermitage Genetics facilities
3

Sharing in the Value Delivered 

  • Conducting 26 product trials across seven countries, involving more than 63,000 pigs, demonstrating the difference our products and services deliver for customers
  • Expanding use of the royalty pricing model, particularly in Europe and Asia (including further contracts in China), so that 77% of our volumes are now conducted on a royalty basis
4

Priorities for 2018

  • Continuing to implement our global strategy, tailored to local markets where needed

  • Expanding use of the royalty model where possible, particularly accelerating the transition in China

  • Making further investments in our supply chain to underpin growth

  • Continuing to collaborate with colleagues and partners on new technologies and on plans to commercialise and achieve regulatory acceptance for gene-edited animals

arrow